Reduction of fatal complications from combined modality therapy in Hodgkin's disease

J Clin Oncol. 1985 Apr;3(4):501-5. doi: 10.1200/JCO.1985.3.4.501.

Abstract

A total of 464 pathologically staged IA through IIIB Hodgkin's disease patients were evaluated for the risk of developing acute nonlymphocytic leukemia, non-Hodgkin's lymphoma, or a fatal infection after treatment with radiation therapy (RT) alone, initial combined radiation therapy and chemotherapy (CMT), or RT with MOPP administered at relapse. Patients received a standard six cycles of MOPP, and additional maintenance chemotherapy was not administered. Patients receiving total nodal irradiation (TNI) and MOPP chemotherapy have an 11.9% actuarial risk of developing a fatal complication at ten years, as compared to a 0.8% risk for lesser field irradiation and MOPP (P = .005). The risk with RT alone is 0.6%. Patients 40 years of age or older have a greater risk for complications. These data report a low risk for fatal complication with CMT when less than TNI is administered and when maintenance chemotherapy is not used.

Publication types

  • Comparative Study

MeSH terms

  • Actuarial Analysis
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Hodgkin Disease / mortality
  • Hodgkin Disease / therapy*
  • Humans
  • Leukemia, Radiation-Induced / prevention & control
  • Lymph Nodes / radiation effects*
  • Mechlorethamine / administration & dosage
  • Mechlorethamine / adverse effects
  • Middle Aged
  • Pneumonia, Pneumocystis / etiology
  • Pneumonia, Pneumocystis / prevention & control
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Procarbazine / administration & dosage
  • Procarbazine / adverse effects
  • Prognosis
  • Radiation Injuries / prevention & control*
  • Risk
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Prednisone

Supplementary concepts

  • MOPP protocol